You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》安進藥廠(AMGN.US)季度利潤遜預期 市後偏軟
美國安進藥廠(Amgen)(AMGN.US)公布去年第四季業績。季度淨利潤按年跌15%至16.16億美元,每股季度攤薄純利3美元,經調整後為4.09美元,市場預期為4.1美元。季度派息每股1.94美元。季度收入68.39億美元,按年跌不足1%,高於市場預期的67.7億美元。 公司與禮來藥廠(LLY.US)合作生產新冠抗體治療藥,但美國當局去年11月取消對該藥的認證,指該藥不能應對目前變種,導致公司從有關治療銷售的收入減少。公司自家藥物銷售上升,當中骨質疏鬆注射劑保骼麗季度銷售按年升14%至9.92億美元。公司預期現年度銷售介乎260億至272億美元,市場預期為271.7億美元。 安進藥廠股價在市後跌0.4%,報251.35美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account